Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lundgren

Showing results (441-450 of 681) with videos related to

Pageof 69
Sort By:
Annals of Internal Medicine|September 4, 2008
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial, W M El-Sadr, B Grund, et al.
The Journal of Infectious Diseases|June 15, 2004
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA studyUlrik Bak Dragsted, Amanda Mocroft, Stefano Vella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2008
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) studyEllen Tedaldi, Lars Peters, Jacquie Neuhaus, et al.
AIDS (London, England)|August 3, 2023
Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohortAdrian G Zucco, Marc Bennedbæk, Christina Ekenberg, et al.
Cancer|July 28, 2010
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignanciesJoanne Reekie, Csaba Kosa, Frederik Engsig, et al.
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
Antiviral Therapy|May 15, 2002
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA studyA Mocroft, A N Phillips, N Friis-Møller, et al.
Archives of Internal Medicine|April 24, 1995
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in EuropeJ D Lundgren, S E Barton, C Katlama, et al.
Tuberculosis Research and Treatment|April 19, 2021
Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International LaboratoryDaria N Podlekareva, Dorte Bek Folkvardsen, Alena Skrahina, et al.
Respiratory Medicine|April 1, 1995
Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumoniaT L Benfield, R van Steenwijk, T L Nielsen, et al.
Pageof 69

Showing results (441-450 of 681) with videos related to

Sort By:
Pageof 69
Annals of Internal Medicine|September 4, 2008
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial, W M El-Sadr, B Grund, et al.
The Journal of Infectious Diseases|June 15, 2004
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA studyUlrik Bak Dragsted, Amanda Mocroft, Stefano Vella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2008
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) studyEllen Tedaldi, Lars Peters, Jacquie Neuhaus, et al.
AIDS (London, England)|August 3, 2023
Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohortAdrian G Zucco, Marc Bennedbæk, Christina Ekenberg, et al.
Cancer|July 28, 2010
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignanciesJoanne Reekie, Csaba Kosa, Frederik Engsig, et al.
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
Antiviral Therapy|May 15, 2002
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA studyA Mocroft, A N Phillips, N Friis-Møller, et al.
Archives of Internal Medicine|April 24, 1995
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in EuropeJ D Lundgren, S E Barton, C Katlama, et al.
Tuberculosis Research and Treatment|April 19, 2021
Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International LaboratoryDaria N Podlekareva, Dorte Bek Folkvardsen, Alena Skrahina, et al.
Respiratory Medicine|April 1, 1995
Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumoniaT L Benfield, R van Steenwijk, T L Nielsen, et al.
Pageof 69